Press
Releases
| Zinc Dispersible tablets for Management
of Diarrhoea in Infants and Children | | |
Shri Kapil Sibal, Union Minister for Science & Technology
and Earth Sciences today unveiled Zinc dispersible tablets for treatment of diarrhea
in infants and children in a press conference in New Delhi.
Zinc as an
Immunomodulator Agent has been considered as a Novel Treatment for Childhood Infection
particularly: Childhood diarrhoea; Pneumonia and Septicemia. More than 1.5 million
children under five continue to die each year as a result of acute diarrhea. In
India alone, more than 500,000 deaths occur annually due to childhood diarrhoea.
The use of zinc along with oral rehydration therapy (ORT) is recommended by WHO
to decrease the incidence and severity of diarrhea. Government has adopted policy
of use of Zinc in treatment of diarrhoea in National Rural Health Mission in children
< 5 years. DBT & WHO have developed simple, easily dispersible & cheap
zinc tablets for the National Programme. Bharat Immunologicals & Biologicals
Corporation Limited (BIBCOL) a Public Sector Undertaking of the Deptt.of Biotechnology
has established GMP production facility for production of Zinc dispersible tablets.
Zinc
Dispersible tablets, to be given for management of diarrhea in children aged 2
months to 5 years would provide children with 20 mg of elemental zinc supplementation
per day for 10-14 days (10 mg per day for infants less than six months of age).
Zinc Dispersible tablets become syrup after adding breast milk or water. The treatment
should be started from the first day of diarrhea itself and a 14-day course should
be completed even if diarrhea stops. The tablet is not only effective in stopping
diarrhea but also prevents subsequent illness.
The dispersible zinc tablet,
BIBZinc-20mg contains 20 mg of elemental zinc as active ingredient and contains
sweetener and taste masker (Vanilla flavor) and is scored tablet. The product
is in line with the recommendations of WHO. The product is produced with technology
transfer from Nutriset (French Company) through Department of Biotechnology, Ministry
of Science and Technology, Government of India. The Nutriset product has been
tested in Indian fields and clinical trials have evaluated the efficacy of zinc
supplementation and safety.
BIBCOL is ready with tablet manufacturing facility
and trial batch has been produced. The company has a production capacity of 240
million tablets per annum and will soon come with commercial production. BIBCOL
is aiming for standard quality product at lowly price for mass consumption. Source:
Press Inormation Bureau Date: April 07, 2008 |